Determine the necessary mass, volume, or concentration for preparing a solution.
Information
Tenofovir (GS-1278) blocksreverse transcriptaseand hepatitis B virus infections.
In vitro
Tenofovir reduces the viral cytopathic effect of HIV-1(IIIB), HIV-2(ROD) and HIV(EHO) with EC50 of 1.15 μg/mL, 1.12 μg/mL and 1.05 μg/mL in MT-4 cells. Tenofovir also reduces the viral cytopathic effect of SIV(mac251) , SIV(B670) ,SHIV(89.6) and SHIV(RTSHIV). Tenofovir is uniquely active against multinucleoside-resistant HIV expressing the Q151M mutation, but shows reduced susceptibility to the T69S insertion mutations. Tenofovir inhibits hepatitis B virus (HBV) activity in HepG2 2.2.15, HepAD38 and HepAD79 cells. Tenofovir (4 μM) completely inhibits the growth of HIVIIIB in MT-2 cells. Tenofovir inhibits synthesis of negative strand strong-stop DNA with IC50 of 9 µM for wild-type RT, 6 µM for M184V RT and 50 µM for K65R RT.
In vivo
Tenofovir (30 mg/kg) completely prevents SIV infection in all macaques without toxicity. Tenofovir treatment reduces plasma viral RNA levels to undetectable, with parallel decreases in the infectivity of plasma and infectious cells in peripheral blood mononuclear cells and cerebrospinal fluid (CSF) and stabilization of CD4+ T-cell numbers. Tenofovir (30 mg/kg, s.c.) completely abrogates HIV infection via intravaginal exposure in pig-tailed macaques.
Cell Data
cell lines:NSCLC cells
Concentrations:
Incubation Time:
Powder Purity:≥99%
| 溶解度 | Solubility (25°C) In vitro Ethanol: mg/mL |
|---|---|
| 比旋光度[α] | -20° (C=1,0.1mol/L HCl) |
| 融点(°C) | 283 °C |
H318:Causes serious eye damage
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.
P305+P354+P338:IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing.
P317:Get emergency medical help.
当社のグレード選定ガイドでは、カタログ内のすべてのバリエーションについて、純度、安定剤の状態、用途への適合性を網羅しています。
Moligand™ グレードガイドを見る →